Orthofix Medical Inc., a leading global medical technology company, today reported financial results for the third quarter ended September 30, 2026, and revised its full-year 2026 net sales and non-GAAP adjusted EBITDA guidance. Net sales came to $825 million. The filing was published on EDGAR at 13:01 UTC on Monday, 9 November 2026.
The release also reports:
- Total reported net sales of $207.9 million, representing an increase of 1% on a reported basis and 2% on a pro forma constant currency basis compared with the prior year period.
- Reported net loss of $(6.1) million and non-GAAP adjusted EBITDA of $26.0 million.
- Global Spine Fixation 1 net sales increased 1% on a reported and constant currency basis compared with the prior year period.
- Global Limb Reconstruction net sales increased 8% on a reported basis and 9% on a constant currency basis compared with the prior year period.
Outlook: Orthofix is revising its full-year 2026 net sales and adjusted EBITDA guidance.
Form 8-K is the current report that U.S. public companies file with the SEC to disclose significant events between their regular reports. This filing reports Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The press release is attached as Exhibit 99.1.
Source: U.S. Securities and Exchange Commission (EDGAR) filing